The Devastating Impact of Missing Puberty - James Linehan (#5)
20 March 2025
With James Linehan
Global
James Linehan was born with hypogonadism, a condition that left his body unable to trigger puberty naturally. His firsthand account of the developmental, emotional and fertility consequences of prolonged hormonal absence makes him an unusual and important voice in the debate over puberty blockers for gender-questioning young people. In Ireland, where the HSE has been reviewing paediatric gender services in light of international evidence including the 2024 Cass Review, the questions his experience raises about reversibility, vulnerability and long-term harm go directly to the heart of current clinical and policy decisions.
James Linehan was not placed on a gender medicine protocol. His body simply failed to produce the hormones that trigger puberty, due to a condition called hypogonadism. That distinction matters, because everything he experienced — the social exclusion, the emotional immaturity that persisted far beyond adolescence, the lasting effects on his fertility — came not from a clinical decision but from a physiological absence. His account is therefore a rare, extended observation of what life without puberty actually looks like, undistorted by ideological framing in either direction. In this episode of Beyond Gender, Linehan describes growing up in a body that remained physically and socially out of step with everyone around him. He reflects at length on the vulnerability that came with this, a childlike quality that persisted into adulthood and that he believes exposed him to manipulation he would not otherwise have been susceptible to. The emotional and psychological development that puberty drives is not, he argues, a secondary consequence of hormonal change: it is central to the formation of resilience, judgment and social identity. The strongest challenge Linehan's experience poses is to the claim of reversibility. Proponents of puberty blockers for gender-questioning children routinely describe the intervention as a pause — a way of buying time without foreclosing options. Linehan's fertility was not preserved by the delayed start of his hormonal treatment, and the developmental gaps he describes did not simply close once he began medically-induced puberty as an adult. He argues that certain biological and psychological windows are narrower than clinical reassurances tend to suggest. The episode also explores the relationship between puberty and brain development. Linehan raises concerns about the cognitive dimension of adolescent hormone changes, a question that has attracted increasing scientific attention. Both the 2024 Cass Review in the United Kingdom and systematic evidence reviews conducted by Swedish and Finnish health authorities have highlighted the lack of robust long-term data on the neurological effects of GnRH analogues in adolescents — findings that have since influenced policy shifts in several European countries. In Ireland, paediatric gender medicine has been provided through the National Gender Service at Children's Health Ireland at Crumlin, and the HSE has been reviewing its approach in light of the international evidence landscape, including the Cass Review. Linehan's condition is distinct from pharmacologically-induced puberty suppression, and he does not claim direct clinical equivalence. What he does offer is a sustained, lived account of prolonged hormonal absence and its consequences — something that clinical trials of GnRH analogues, given their short follow-up periods, have not been able to provide. Hosts Stella O'Malley and Mia Hughes draw out the implications steadily, asking what parents and clinicians need to understand before pursuing suppression as a first-line response to gender distress in young people. Linehan's answer is rooted in his own decades of experience: that what is framed as a cautious, reversible intervention carries developmental costs that science has not yet adequately mapped, and that children who miss puberty do not simply catch up.
